Advanced Filters
noise

liver-disorders Clinical Trials

A listing of liver-disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,510 clinical trials
M Meng Maobin M, MD

Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer

A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites

18 - 75 years of age All Phase 2
Y Ying Wu, Dr.

Effectiveness and Safety of Probiotics in Protecting Liver Function

To evaluate the effectiveness and safety of using probiotics to protect the liver function of long-term alcohol consumers

19 - 65 years of age All Phase N/A
D Dou-Sheng Bai, MD

Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients

In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance postoperative immune function and thereby improve patient outcomes.

18 years of age All Phase N/A
J Jakob Kirkegård, MD, PhD

Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.

18 - 99 years of age All Phase N/A
y yinan shen

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to …

18 - 75 years of age All Phase 1
X Xiujun Cai, MD

The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after extensive hepatectomy. The bioartificial liver device consists of clinical-grade human-induced hepatocytes (hiHep) generated from human …

30 - 80 years of age All Phase N/A
L Liao Wei

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes

18 - 75 years of age All Phase 2
J Johannes Häberle, Prof Dr

Liver Metabolic Functions in Patients With Citrin Deficiency and Healthy Subjects

Citrin is an aspartate-glutamate transporter in the liver that facilitates the urea cycle pathway for ammonia detoxification via ureagenesis. It is also thought to be involved in liver energy metabolism as a component of the malate-aspartate shuttle. The clinical presentation in patients supports the hypothesis that liver glycolytic, gluconeogenic and …

18 - 65 years of age All Phase N/A
X Xingshun Qi, MD

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human …

18 years of age All Phase N/A
W Wen-Na Li, Dr.

Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis

It is still not clear whether rifaximin can prevent the progression of liver cirrhosis, reduce the overall complications and improve the survival in patients with decompensated cirrhosis. This is a multi-center open-labelled randomized prospective study to evaluate the efficacy and safety of rifaximin in preventing the progression and complications in …

18 - 80 years of age All Phase N/A

Simplify language using AI